We earn a commission from brands on this page, which impacts their display. Advertising disclosure

Compare GLP-1 providers

Explainer

Why the food noise goes quiet

By the TreatmentMD editorial team

Updated 6 min read

A smiling woman in a white T-shirt with one hand resting on her stomach

Key takeaways

  • GLP-1 medicines mimic a hormone your body already makes, which helps tell your brain you've had enough.U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.All sources
  • That's why many people find the constant chatter about food, often called food noise, gets much quieter.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources
  • It can feel less dramatic after the first few months. That's expected, and the medicine is still working.The American Journal of Clinical NutritionSourceTronieri JS, Allison KC, DeRouen K, et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. Am J Clin Nutr. 2026;124(2):101403.Open the source All sources

By the TreatmentMD editorial team

If part of your brain always seems to be thinking about food, you're far from alone. Lots of people call it food noise.

Many people on a GLP-1 say it finally goes quiet.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources So here's what's going on, in plain English, and what to expect over time.

01Food noise

What is food noise?

It's the popular name for constant thoughts about food: what's in the fridge, what you'll have next, the snack you promised yourself you'd skip.

Thinking about food is normal. It becomes food noise when the thoughts bother you or get in the way of your day.Harvard Health PublishingSourceHarvard Health Publishing. Understanding food noise, and how to turn down the volume. February 25, 2026.Open the source All sources And you're in good company: in a 2026 survey, about half of U.S. adults said they have it at least sometimes.Obesity Science & PracticeSourceHayashi D, Masterson TD. Prevalence and correlates of perceived food noise among U.S. adults in a nationally representative sample. Obes Sci Pract. 2026;12(5):e70201.Open the source All sources

The phrase took off in 2023, as people on GLP-1s started describing the chatter going quiet.NutrientsSourceHayashi D, Edwards C, Emond JA, et al. What is food noise? A conceptual model of food cue reactivity. Nutrients. 2023;15(22):4809.Open the source All sources It isn't a medical diagnosis, though researchers have since built questionnaires to measure it.ObesitySourceDiktas HE, Cardel MI, Foster GD, et al. Development and validation of the Food Noise Questionnaire. Obesity (Silver Spring). 2025;33(2):289-297.Open the source All sources The Endocrine Society describes it as persistent, intrusive thoughts about food.Endocrine SocietySourceJastreboff AM, Ard JD, Hall KD, et al. Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement. Endocr Rev. 2026.Open the source All sourcesObesitySourceAlexander L, Purnell JQ, Burridge K, et al. Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach. Obesity (Silver Spring). 2026;34(4):851-870.Open the source All sources

And no, it isn't a lack of willpower, so getting help with it isn't cheating. Hunger and fullness are run by hormones and signals between your gut and your brain, which is exactly where GLP-1s come in.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

02How it works

What does GLP-1 do?

GLP-1 is a hormone your gut makes when you eat. It helps tell your brain you've had enough, and it slows how fast your stomach empties.U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.All sourcesThe American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

Your own GLP-1 is gone within a couple of minutes, though, so its message is short and sweet.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

GLP-1 medicines mimic that hormone, and they're built to last. A weekly shot or a daily pill keeps the signal going around the clock.U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.All sources

In short, they reduce appetite, slow how fast the stomach empties and increase the feeling of fullness after eating.U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.All sourcesDiabetes, Obesity and MetabolismRandomized trial · 2021At week 20, people on semaglutide ate 35% less at an all-you-can-eat lunch than on placebo, and reported less hunger and fewer cravings.72 people · 20 weeks. Adults with obesity. Funded by Novo Nordisk.The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Friedrichsen M, et al., 2021.Read the study All sources

03Your brain

Why does food noise go quiet?

Mostly because of your brain. GLP-1 receptors sit in several areas of the brain that handle appetite, and the medicines switch them on.U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.All sources

They also touch the brain's reward system, which runs on dopamine and drives the "I really want that" feeling. Brain scans show changes there too, which may be why cravings ease.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

The slower stomach helps you feel full, mostly in the first weeks. That effect tends to fade over time, while the appetite effect keeps going.U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.All sourcesBMJ Open Diabetes Research & CareSourceAmerican Diabetes Association Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of Care in Overweight and Obesity. BMJ Open Diabetes Res Care. 2026;13(Suppl 1):e005729.Open the source All sources

So it's your biology doing the heavy lifting, not you white-knuckling it.Endocrine SocietySourceJastreboff AM, Ard JD, Hall KD, et al. Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement. Endocr Rev. 2026.Open the source All sources

04Hunger and cravings

Is it hunger, cravings or both?

Both, and they're a little different. Hunger is your body asking for food. A craving is wanting one food in particular, often something rich or sweet.

Food noise is different again. A craving usually fades once you've had the food, while food noise can keep going, even mid-meal.Obesity Action CoalitionSourceObesity Action Coalition. Everything you need to know about food noise. October 24, 2025.Open the source All sources

In studies, people on GLP-1 medicines felt less hungry, felt full sooner and had fewer, weaker cravings.Diabetes, Obesity and MetabolismRandomized trial · 2021At week 20, people on semaglutide ate 35% less at an all-you-can-eat lunch than on placebo, and reported less hunger and fewer cravings.72 people · 20 weeks. Adults with obesity. Funded by Novo Nordisk.The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Friedrichsen M, et al., 2021.Read the study All sourcesNature MedicineRandomized trial · 2025By week 3, people on tirzepatide ate less at a test meal and reported fewer cravings for high-fat foods, sweets and fast food than on placebo.114 people · 6 weeks. Adults with overweight or obesity, without diabetes. Funded by Eli Lilly.Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Martin CK, et al., 2025.Read the study All sources

The biggest drops were for rich, sweet, starchy and fast foods. Cravings for fruit and vegetables didn't budge.Nature MedicineRandomized trial · 2025By week 3, people on tirzepatide ate less at a test meal and reported fewer cravings for high-fat foods, sweets and fast food than on placebo.114 people · 6 weeks. Adults with overweight or obesity, without diabetes. Funded by Eli Lilly.Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Martin CK, et al., 2025.Read the study All sources

People ate less, too. In one study, people on semaglutide ate about a third less at an all-you-can-eat lunch.Diabetes, Obesity and MetabolismRandomized trial · 2021At week 20, people on semaglutide ate 35% less at an all-you-can-eat lunch than on placebo, and reported less hunger and fewer cravings.72 people · 20 weeks. Adults with obesity. Funded by Novo Nordisk.The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Friedrichsen M, et al., 2021.Read the study All sources

And they didn't have to try harder to get there. Their effort to hold back stayed the same; they simply wanted less.Nature MedicineRandomized trial · 2025By week 3, people on tirzepatide ate less at a test meal and reported fewer cravings for high-fat foods, sweets and fast food than on placebo.114 people · 6 weeks. Adults with overweight or obesity, without diabetes. Funded by Eli Lilly.Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Martin CK, et al., 2025.Read the study All sources

05Everyone's different

When does food noise go quiet?

Often within the first few weeks, though everyone's different. In one study, hunger and cravings were already lower after three weeks.Nature MedicineRandomized trial · 2025By week 3, people on tirzepatide ate less at a test meal and reported fewer cravings for high-fat foods, sweets and fast food than on placebo.114 people · 6 weeks. Adults with overweight or obesity, without diabetes. Funded by Eli Lilly.Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Martin CK, et al., 2025.Read the study All sources

If you don't notice a big change, the medicine can still be doing its job. In studies, people ate less even when they didn't feel much different.The American Journal of Clinical NutritionSourceTronieri JS, Allison KC, DeRouen K, et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. Am J Clin Nutr. 2026;124(2):101403.Open the source All sources

Doses also start low and step up over a few months, so give it a little time. Here's why GLP-1s start low.

06Over time

Does food noise come back?

A smiling bald man with a graying beard in a white T-shirt

It can feel less dramatic after the first few months, and that's completely normal.The American Journal of Clinical NutritionSourceTronieri JS, Allison KC, DeRouen K, et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. Am J Clin Nutr. 2026;124(2):101403.Open the source All sources

In a 60-week study of semaglutide, the quieter food thoughts were clearest in the first 20 weeks. By weeks 40 to 60, people's hunger ratings looked much like the placebo group's.The American Journal of Clinical NutritionSourceTronieri JS, Allison KC, DeRouen K, et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. Am J Clin Nutr. 2026;124(2):101403.Open the source All sources

Yet they were still eating about a quarter fewer calories at lunch, and they kept the weight off.The American Journal of Clinical NutritionSourceTronieri JS, Allison KC, DeRouen K, et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. Am J Clin Nutr. 2026;124(2):101403.Open the source All sources

So if a little hunger wanders back, it doesn't mean the medicine has stopped working.The American Journal of Clinical NutritionSourceTronieri JS, Allison KC, DeRouen K, et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. Am J Clin Nutr. 2026;124(2):101403.Open the source All sources

Experts think it's your body settling at its new weight, with appetite coming partly back to help hold you there.Endocrine SocietySourceJastreboff AM, Ard JD, Hall KD, et al. Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement. Endocr Rev. 2026.Open the source All sources If it feels like a big change, mention it to your clinician, who can look at your plan with you.

07Stopping

What happens if you stop?

The medicine clears from your body over a few weeks, and your appetite and cravings drift back toward where they were.U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.All sourcesCleveland ClinicSourceCleveland Clinic. What happens when you stop taking a GLP-1? September 29, 2026.Open the source All sources

There's usually no withdrawal, just your usual appetite coming back.Cleveland ClinicSourceCleveland Clinic. What happens when you stop taking a GLP-1? September 29, 2026.Open the source All sources

That's biology, not failure. Habits you build now make the change easier.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources Our guide to stopping a GLP-1 has more.

08Beyond food

Can GLP-1s quiet other cravings, like alcohol?

Some people find they want a glass of wine less often, too.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

Scientists are taking it seriously. In early studies of semaglutide in people who drink heavily, they had fewer heavy drinking days and less craving.JAMASourceHendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395-405.Open the source All sourcesThe LancetSourceKlausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10540):1687-1698.Open the source All sources

It's still early, and these medicines aren't approved for drinking or other habits.U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.All sources If that's something you'd like help with, mention it to your clinician.

09Easy habits

How can you make the most of the quiet?

A few small habits help:

  1. Eat at regular times

    Small, regular meals stop you getting overly hungry, which can bring cravings back.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

  2. Protein first

    Eat it first, before you fill up.Cleveland ClinicSourceCleveland Clinic. Taking GLP-1s? Make sure you exercise. May 5, 2026.Open the source All sources

  3. Eat slowly

    Your brain can take up to 30 minutes to notice you're full.Cleveland ClinicSourceCleveland Clinic. How to manage the digestive side effects of GLP-1 medications. September 9, 2026.Open the source All sources

  4. Sleep and stress count

    Poor sleep and stress can turn hunger and cravings back up.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

  5. Keep the treats

    No need to give them up, just keep the portions small.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

  6. Speak up

    If food stops being enjoyable or your mood dips, tell your clinician.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

10Getting started

Ready to get started?

A good program checks in on how you're feeling, appetite included, and adjusts your plan with you. Our ranking compares the programs we rank, and our guide to what to eat on a GLP-1 has easy meal ideas.

Frequently asked questions.

Why am I still hungry on a GLP-1?

That's normal.

These medicines turn appetite down rather than off.

Doses start low, too, and long gaps between meals, poor sleep and stress can all turn hunger up.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

If you're still very hungry, your clinician can adjust your plan.

Do the pills quiet food noise too?

They work on the same switch.

The Wegovy® pill is semaglutide, and Foundayo™ turns on the same GLP-1 receptor, so both turn appetite down.U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.All sources

Does tirzepatide quiet it more than semaglutide?

Both turn appetite down.

One study compared them side by side in people with type 2 diabetes, and the drop in appetite was about the same.American Diabetes AssociationSourceHeise T, DeVries JH, Urva S, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(5):998-1004.Open the source All sources

Why do I still crave sweets sometimes?

It's common, so don't beat yourself up.

Feeling queasy can make comfort food more tempting, and so can going too long without eating.

Small, regular meals help.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

Will I stop enjoying food?

Some people find food a little less exciting, which is part of how it works.

If it stops being enjoyable at all, or your mood dips, tell your clinician, who can adjust your plan.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

Can you quiet food noise without a GLP-1?

Some easy habits can help: regular, balanced meals with protein and fiber, and eating a bit more mindfully.

Strict dieting and skipped meals tend to turn it up.Harvard Health PublishingSourceHarvard Health Publishing. Understanding food noise, and how to turn down the volume. February 25, 2026.Open the source All sources

Supplements sold as "natural Ozempic" are a different story; our myths article looks at them.

Does it help with emotional eating or bingeing?

Often, yes.

Studies report less emotional eating and fewer binges, though these medicines aren't approved to treat binge eating disorder.U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.All sourcesThe American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sourcesBMJ Open Diabetes Research & CareSourceAmerican Diabetes Association Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of Care in Overweight and Obesity. BMJ Open Diabetes Res Care. 2026;13(Suppl 1):e005729.Open the source All sources If emotional eating is a big part of the picture, extra support from your clinician or a therapist helps too.The American Journal of Clinical NutritionSourceMozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367.Open the source All sources

Does it wear off before my next dose?

Some people say their appetite creeps back toward the end of the week.

Stick to your schedule rather than taking a dose early, and mention it to your clinician.U.S. Food and Drug AdministrationSourceFDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.All sources

The bottom line

GLP-1 medicines quiet food noise mainly by working on the parts of your brain that handle appetite, with a slower stomach helping early on.

The quiet can ease a little over time while the medicine keeps working, and a few good habits make the most of it.

When you're ready, compare programs on our ranking to find one that fits.

By the TreatmentMD editorial team

Medical disclaimerThis content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting any weight-loss program or medication. Individual results may vary.

Sources19 sources, and product and safety information
  1. 1FDA prescribing information for Wegovy® (injection and tablets), Zepbound® and Foundayo™: Indications and Usage; Dosage and Administration; Clinical Pharmacology.
  2. 2Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. doi.org
  3. 3Tronieri JS, Allison KC, DeRouen K, et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. Am J Clin Nutr. 2026;124(2):101403. doi.org
  4. 4Harvard Health Publishing. Understanding food noise, and how to turn down the volume. February 25, 2026. health.harvard.edu
  5. 5Hayashi D, Masterson TD. Prevalence and correlates of perceived food noise among U.S. adults in a nationally representative sample. Obes Sci Pract. 2026;12(5):e70201. doi.org
  6. 6Hayashi D, Edwards C, Emond JA, et al. What is food noise? A conceptual model of food cue reactivity. Nutrients. 2023;15(22):4809. doi.org
  7. 7Diktas HE, Cardel MI, Foster GD, et al. Development and validation of the Food Noise Questionnaire. Obesity (Silver Spring). 2025;33(2):289-297. doi.org
  8. 8Jastreboff AM, Ard JD, Hall KD, et al. Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement. Endocr Rev. 2026. doi.org
  9. 9Alexander L, Purnell JQ, Burridge K, et al. Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach. Obesity (Silver Spring). 2026;34(4):851-870. doi.org
  10. 10Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. doi.org
  11. 11American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of Care in Overweight and Obesity. BMJ Open Diabetes Res Care. 2026;13(Suppl 1):e005729. doi.org
  12. 12Obesity Action Coalition. Everything you need to know about food noise. October 24, 2025. obesityaction.org
  13. 13Martin CK, Carmichael OT, Carnell S, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025;31(9):3141-3150. doi.org
  14. 14Cleveland Clinic. What happens when you stop taking a GLP-1? September 29, 2026. clevelandclinic.org
  15. 15Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395-405. doi.org
  16. 16Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10540):1687-1698. doi.org
  17. 17Cleveland Clinic. Taking GLP-1s? Make sure you exercise. May 5, 2026. clevelandclinic.org
  18. 18Cleveland Clinic. How to manage the digestive side effects of GLP-1 medications. September 9, 2026. clevelandclinic.org
  19. 19Heise T, DeVries JH, Urva S, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(5):998-1004. doi.org

Product information

  • Zepbound® (tirzepatide) is a prescription-only injectable medication FDA-approved for chronic weight management in adults with obesity, or adults with overweight who have at least one weight-related medical condition. It is also approved for the treatment of moderate to severe obstructive sleep apnea in adults with obesity, and should be used in combination with a reduced-calorie diet and increased physical activity.
  • Ozempic® (semaglutide) is a prescription-only injectable medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. It is not FDA-approved for weight loss; however, weight reduction has been observed in some individuals with type 2 diabetes using the medication.
  • Mounjaro® (tirzepatide) is a prescription-only injectable medication FDA-approved for the treatment of type 2 diabetes. It is not FDA-approved for weight loss; however, weight reduction has been observed in some individuals using the medication.
  • Wegovy® (semaglutide) is a prescription-only injectable or oral medication FDA-approved for chronic weight management in adults with obesity, or adults with overweight and at least one weight-related medical condition, when used alongside a reduced-calorie diet and increased physical activity.
  • All medications require a medical evaluation and prescription from a licensed healthcare provider. Individual results may vary.

Important safety information

  • Compounded semaglutide and tirzepatide are prepared by state-licensed pharmacies and are not FDA approved. The FDA does not review their safety, effectiveness or quality, and clinical trial results for brand-name drugs do not carry over to them.
  • Semaglutide and tirzepatide carry a boxed warning for a risk of thyroid C-cell tumors, based on animal studies, and are not for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, or who is pregnant. Other warnings include pancreatitis, gallbladder problems, and a higher risk of low blood sugar when combined with insulin or a sulfonylurea. The most common side effects are digestive, such as nausea, vomiting, diarrhea and constipation.
  • This is a high-level summary, not a complete list. A licensed clinician will review your health history to decide whether a GLP-1 medication is right for you.

Our #1 pick

Ready to start? welludr. is our pick.

The lowest advertised price on our list, with unlimited clinician messaging.

Visit welludr.Compare providers